



NDA 21-257/S-018

SUPPLEMENT APPROVAL

Alcon Universal, Ltd.
c/o Alcon Research, Ltd.
Attention: Angela C. Kothe, O.D., Ph.D.
Director, Regulatory Affairs
6201 South Freeway
Fort Worth, Texas 76134-2099

Dear Dr. Kothe:

Please refer to your supplemental new drug application dated June 1, 2006, received June 2, 2006, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Travatan (travoprost ophthalmic solution) 0.004%.

We acknowledge receipt of your submissions dated September 27, 2006, March 29, 2007, June 24, 2008, and July 7 and 13, and August 19, 2010.

This "Prior Approval" supplemental new drug application provides for the use of Travatan (travoprost ophthalmic solution) 0.004% for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension.

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

As soon as possible, but no later than 14 days from the date of this letter, submit, using the FDA automated drug registration and listing system (eLIST), the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format, as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>, that is identical to the enclosed labeling (text for the package insert) and include the labeling changes proposed in any pending "Changes Being Effected" (CBE) supplements. Information on submitting SPL files using eLIST may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As" at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications for this NDA, including pending "Changes Being Effected" (CBE) supplements, for which FDA has not yet issued an

action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format that includes the changes approved in this supplemental application.

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

We are waiving the pediatric study requirement for this application because there is evidence suggesting that the drug product would be unsafe in all pediatric age groups. There are potential safety concerns related to increased pigmentation following long-term chronic use of the drug product.

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit the following, in triplicate, (1) a cover letter requesting advisory comments, (2) the proposed materials in draft or mock-up form with annotated references, and (3) the package insert(s) to:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Drug Marketing, Advertising, and Communications
5901-B Ammendale Road
Beltsville, MD 20705-1266

You must submit final promotional materials and package insert(s), accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.(b)(3)(i)]. Form FDA 2253 is available at <http://www.fda.gov/opacom/morechoices/fdaforms/cder.html>; instructions are provided on page 2 of the form. For more information about submission of promotional materials to the Division of Drug Marketing, Advertising, and Communications (DDMAC), see <http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm>.

If you decide to issue a letter communicating important safety-related information about this drug product (i.e., a “Dear Health Care Professional” letter), we request that you submit, at least 24 hours prior to issuing the letter, an electronic copy of the letter to this NDA, to CDERMedWatchSafetyAlerts@fda.hhs.gov, and to the following address:

MedWatch Program
Office of Special Health Issues
Food and Drug Administration
10903 New Hampshire Ave
Building 32, Mail Stop 5353
Silver Spring, MD 20993

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Michael Puglisi, Project Manager, at (301) 796-0791.

Sincerely,

{See appended electronic signature page}

Wiley A. Chambers, M.D.
Acting Director
Division of Anti-Infective
and Ophthalmology Products
Office of Antimicrobial Products
Center for Drug Evaluation and Research

Enclosure:

Content of Labeling

Application Type/Number	Submission Type/Number	Submitter Name	Product Name
NDA-21257	SUPPL-18	ALCON INC	TRAVATAN(TRAVOPROST OPTHALMIC SOLUTION)

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

WILEY A CHAMBERS
08/31/2010